Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel

Clinical Cardiology

Volumn 33, Issue 4, 2010, Pages 206-212

  Husted, Steen ^a   Storey, Robert F ^b   Harrington, Robert A ^c   Emanuelsson, Håkan ^d   Cannon, Christopher P ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; FIBRINOGEN RECEPTOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MYELOPEROXIDASE; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; ADENOSINE; ASPIRIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PEROXIDASE; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 77950848980     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20732     Document Type: Article

References (40)

1. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65:S253-S259.
2. Lucas AR, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about acute coronary syndromes. Circulation. 2006;113:e728-e732. (Pubitemid 43755168)
3. Khuseyinova N, Koenig W. Biomarkers of outcome from cardiovascular disease. Curr Opin Crit Care. 2006;12:412-419. (Pubitemid 44341705)
4. Tousoulis D, Antoniades C, Koumallos N, et al. Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev. 2006;17:225-233. (Pubitemid 44038615)
5. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes, part I: introduction and cytokines. Circulation. 2006;113:e72-e75. (Pubitemid 43754285)
6. Bisoendial RJ, Kastelein JJ, Peters SL, et al. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res. 2007;48:952-960.
7. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol. 2001;115:3-12. (Pubitemid 32995086)
8. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372-1378. (Pubitemid 30169857)
9. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547-1560.
10. Parikh SV, de Lemos JA. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci. 2006;332:186-197. (Pubitemid 44563805)
11. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111. (Pubitemid 36337321)
12. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079-2084. (Pubitemid 29196789)
13. Lee KW, Lip GY, Tayebjee M, et al. Circulating endothelial cells, vonWillebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood. 2005;105:526-532. (Pubitemid 40070731)
14. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI IIAsubstudy. J Am Coll Cardiol. 1998;31:1460-1465. (Pubitemid 28273285)
15. Scirica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007;53:1800-1807. (Pubitemid 47509673)
16. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440-1445. (Pubitemid 37176448)
17. Zairis MN, Adamopoulou EN, Manousakis SJ, et al; for the Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs Creactive protein and other inflammatory biomarkers on longterm cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis. 2007;194:397-402.
18. Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol. 2007;99:1364-1368. (Pubitemid 46686633)
19. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart. 2001;86:649-655. (Pubitemid 33086881)
20. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049-1052. (Pubitemid 37071512)
21. Ruggeri ZM. Platelets in atherothrombosis. Nature Med. 2002;8: 1227-1234.
22. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des. 2006;12:1255-1259.
23. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
24. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047.
25. Woodward M, Lowe GD, Francis LM, et al. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2:1934-1940. (Pubitemid 40192746)
26. Chen YG, Xu F, Zhang Y, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J. 2006;119:32-36.
27. Azar RR, Kassab R, Zoghbi A, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J. 2006;151:521.e1-521.e4. (Pubitemid 43144760)
28. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2007;50:1844-1851. (Pubitemid 350007959)
29. Yusuf S, Zhao F, Mehta SR, et al; for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:494-502.
30. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852-1856. (Pubitemid 350017792)
31. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
32. Hartford M, Wiklund O,MattssonHultén L, et al. CRP, interleukin- 6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol. 2006;108:55-62. (Pubitemid 43324907)
33. Palmerini T, Barozzi C, Tomasi L, et al. A randomised study comparing the antiplatelet and anti-inflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study. Thromb Res. 2009;. doi:10.1016/j.thromres.2009.06.016. Available at: http://www. sciencedirect.com.
34. Wang J, Zhang S, Jin Y, et al. Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol. 2007;115:361-365. (Pubitemid 46185636)
35. Antonino MJ, Mahla E, Bliden KP, et al. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol. 2009;103:1546-1550.
36. Ivandic BT, Spanuth E, Haase D, et al. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem. 2007;53:1231-1234. (Pubitemid 47020978)
37. Saw J,Madsen EH, Chan S, et al. TheELAPSE (Evaluation of Long- Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol. 2008;52:1826-1833.
38. Molero L, López-Farré A, Mateos-Cáceres PJ, et al. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol. 2005;146:419-424.
39. Pels K, Schwimmbeck PL, Rosenthal P, et al. Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-?β and activator protein 1 activation in pigs. Eur J Clin Invest. 2009;39:174-182.
40. Winning J, Reichel J, Eisenhut Y, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009;20:50-57.